Adagrasib
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2].
Product Specifications
CAS Number
2326521-71-3
Product Name Alternative
MRTX849
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mrtx849.html
Concentration
10mM
Purity
99.79
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C(CN(C4=C5C(Cl)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1
Molecular Formula
C32H35ClFN7O2
Molecular Weight
604.12
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
K-Ras
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Sutimlimab Biosimilar - Research Grade
